BriaCell Therapeutics Announces Closing of $8.5 Million Offering
September 12 2024 - 4:05PM
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT)
(“BriaCell” or the “Company”), a clinical-stage biotechnology
company that develops novel immunotherapies to transform cancer
care, today announced the closing of its previously announced
best-efforts offering priced at-the-market under Nasdaq rules for
12,325,000 common shares. Each common share was sold at an offering
price of $0.69 per share, for gross proceeds of approximately $8.5
million, before deducting placement agent fees and other offering
expenses. All the shares in the offering were offered by the
Company.
The Company intends to use the net proceeds from
the offering for working capital requirements, general corporate
purposes, and the advancement of business objectives.
ThinkEquity acted as sole placement agent for
the offering.
The securities were offered and sold pursuant to
the Company’s currently effective shelf registration statement on
Form S-3 (File No. 333-276650), including a base prospectus, filed
with the U.S. Securities and Exchange Commission (the “SEC”) on
January 22, 2024 and declared effective on January 31, 2024. The
offering was made by means of a prospectus supplement and
prospectus which have been filed with the SEC and available on the
SEC’s website at www.sec.gov. You should read the applicable
prospectus supplement and prospectus for more complete information
about the Company and the offering. You may obtain these documents
free of charge by visiting the SEC website at www.sec.gov.
Alternatively, you may obtain copies by contacting ThinkEquity, 17
State Street, 41st Floor, New York, New York 10004.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About BriaCell Therapeutics
Corp.BriaCell is a clinical-stage biotechnology company
that develops novel immunotherapies to transform cancer care. More
information is available at https://briacell.com/.
Forward-Looking StatementsThis
press release contains “forward-looking statements” that are
subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of
words such as “anticipate,” “believe,” “contemplate,” “could,”
“estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,”
“potential,” “predict,” “project,” “target,” “aim,” “should,”
“will,” “would,” or the negative of these words or other similar
expressions, although not all forward-looking statements contain
these words. Forward-looking statements, including those about
BriaCell replicating positive data in its ongoing Phase 3 study;
BriaCell’s Bria-IMT™ regimen bringing relief to cancer patients
whose medical needs remain unmet; and the Bria-IMT™ regimen
becoming a therapeutic option for metastatic breast cancer
patients, are based on BriaCell’s current expectations and are
subject to inherent uncertainties, risks, and assumptions that are
difficult to predict. Further, certain forward-looking statements
are based on assumptions as to future events that may not prove to
be accurate. These and other risks and uncertainties are described
more fully under the heading “Risks and Uncertainties” in the
Company’s most recent Management’s Discussion and Analysis, under
the heading “Risk Factors” in the Company’s most recent Annual
Information Form, and under “Risks and Uncertainties” in the
Company’s other filings with the Canadian securities regulatory
authorities and the U.S. Securities and Exchange Commission, all of
which are available under the Company’s profiles on SEDAR+
at www.sedarplus.ca and on EDGAR at
www.sec.gov. Forward-looking statements contained
in this announcement are made as of this date, and BriaCell
Therapeutics Corp. undertakes no duty to update such information
except as required under applicable law.
Neither the Toronto Stock Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the Toronto Stock Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Company Contact:William V.
Williams, MDPresident & CEO1-888-485-6340info@briacell.com
Media Relations:Jules
AbrahamCORE IRjulesa@coreir.com
Investor Relations Contact:CORE
IRinvestors@briacell.com
BriaCell Therapeutics (TSX:BCT)
Historical Stock Chart
From Oct 2024 to Nov 2024
BriaCell Therapeutics (TSX:BCT)
Historical Stock Chart
From Nov 2023 to Nov 2024